Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Akhurst

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 2017
Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapyRichard Ashley Cox, Tim Akhurst, Mathias Bressel, et al.
EJNMMI Reports|June 6, 2024
Response to COVID-19 vaccination imaged by PD-L1 PET scanningMichael P MacManus, Tim Akhurst, Sharon R Lewin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 13, 2003
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncologyThomas Beyer, Gerald Antoch, Todd Blodgett, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 24, 2020
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CTLamiaa Zidan, Amir Iravani, Grace Kong, et al.
Clinical Genitourinary Cancer|March 8, 2021
Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case SeriesAmir Iravani, Catherine Mitchell, Tim Akhurst, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
PET Scanning with (18)F 2-Fluoro-2-Deoxy-D-Glucose (FDG) in Patients with Melanoma. Benefits and LimitationsAn T. Nguyen, Tim Akhurst, Steven M. Larson, et al.
Journal of the American College of Surgeons|July 2, 2003
A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patientsHarvey G Moore, Tim Akhurst, Steven M Larson, et al.
Leukemia & Lymphoma|August 16, 2021
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTENImogen Caldwell, David Byrne, Stephen Lade, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 29, 2016
High clinical and morphologic response using <sup>90</sup>Y-DOTA-octreotate sequenced with <sup>177</sup>Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumoursGrace Kong, Jason Callahan, Michael S Hofman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 16, 2014
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedsideJeremy Lewin, Carleen Cullinane, Tim Akhurst, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 2017
Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapyRichard Ashley Cox, Tim Akhurst, Mathias Bressel, et al.
EJNMMI Reports|June 6, 2024
Response to COVID-19 vaccination imaged by PD-L1 PET scanningMichael P MacManus, Tim Akhurst, Sharon R Lewin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 13, 2003
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncologyThomas Beyer, Gerald Antoch, Todd Blodgett, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 24, 2020
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CTLamiaa Zidan, Amir Iravani, Grace Kong, et al.
Clinical Genitourinary Cancer|March 8, 2021
Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case SeriesAmir Iravani, Catherine Mitchell, Tim Akhurst, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
PET Scanning with (18)F 2-Fluoro-2-Deoxy-D-Glucose (FDG) in Patients with Melanoma. Benefits and LimitationsAn T. Nguyen, Tim Akhurst, Steven M. Larson, et al.
Journal of the American College of Surgeons|July 2, 2003
A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patientsHarvey G Moore, Tim Akhurst, Steven M Larson, et al.
Leukemia & Lymphoma|August 16, 2021
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTENImogen Caldwell, David Byrne, Stephen Lade, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 29, 2016
High clinical and morphologic response using <sup>90</sup>Y-DOTA-octreotate sequenced with <sup>177</sup>Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumoursGrace Kong, Jason Callahan, Michael S Hofman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 16, 2014
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedsideJeremy Lewin, Carleen Cullinane, Tim Akhurst, et al.
Pageof 7